Logical Memory News Today

Mounting research links poverty and other elements of neighborhood deprivation to worse cognition in people with epilepsy.

Western Sydney University's NICM Health Research Institute has led a world-first clinical trial in Australia that offers new hope in the treatment of mild cognitive impairment (MCI) among older people.

1. Lecanemab was associated with reduced amyloid markers in early Alzheimer’s disease as compared to placebo. 2. Lecanemab also resulted in moderately less decline in cognitive and functional measures at 18-month follow-up as compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Rates of Alzheimer’s disease are increasing annually, introducing a considerable burden to

1. Lecanemab was associated with reduced amyloid markers in early Alzheimer’s disease as compared to placebo. 2. Lecanemab also resulted in moderately less decline in cognitive and functional measures at 18-month follow-up as compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Rates of Alzheimer’s disease are increasing annually, introducing a considerable burden to

Researchers assessed the functional and microstructural brain abnormalities, tiredness, and cognitive impairment after mild coronavirus disease 2019 (COVID-19).